Neuropace

Neuropace ROCE

The Return on Capital Employed (ROCE) of Neuropace (NPCE) as of Oct 4, 2026 is -88.40 %. In the previous year, Return on Capital Employed (ROCE) was -266.65 % — a change of -66.85% (higher).

ROCE

-88.40 %

YoY

-66.85%

Last updated:

In 2026, Neuropace's return on capital employed (ROCE) was -88.40 %, a -66.85% increase from the -266.65 % ROCE in the previous year.

The Neuropace ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
16.04 USD
Jan 1, 2020
8.68 USD
Jan 1, 2021
-39.01 USD
Jan 1, 2022
-118.27 USD
Jan 1, 2023
-133.09 USD
Jan 1, 2024
-266.65 USD
Jan 1, 2025
-88.40 USD
The Neuropace ROCE history
YEARROCEYoY
-88.40 %-66.85%
-266.65 %+100.35%
-133.09 %+12.53%
-118.27 %+203.22%
-39.01 %-549.33%
8.68 %-45.88%
16.04 %—
Access this data via the Eulerpool API

Neuropace Stock analysis

What does Neuropace do? Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Neuropace's Return on Capital Employed (ROCE)

Neuropace's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Neuropace's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Neuropace's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Neuropace’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Neuropace stock

Return on Capital Employed (ROCE) of Neuropace is -88.40 % in 2026.

Return on Capital Employed (ROCE) of Neuropace changed from -266.65 % to -88.40 %, representing a -66.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Neuropace since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Neuropace with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Neuropace

All Key Metrics — Neuropace